IL1B and metabolic dysfunction-associated steatotic liver disease: In preclinical animal models, Resmetirom administration significantly decreased liver weight, hepatic lipid content, plasma alanine aminotransferase (ALT) activity, and hepatic/plasma cholesterol concentrations, consequently improving NAFLD activity scores (NAS) (Kannt et al., 2021), which suggests that Resmetirom may mitigate lipid peroxidation and its anti-inflammatory properties (e.g., suppression of tumor necrosis factor-α [TNF-α] and interleukin-1β [IL-1β]) may attenuate inflammation-driven dysregulation of iron metabolism.